Vectibix
Payments companies reported to CMS as associated with Vectibix. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Vectibix, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Vectibix
These are the largest totals companies reported as associated with Vectibix. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Vijay Gunuganti | San Antonio, TX | Medical Oncology | $40,235.53 |
| Miguel Albino | Austin, TX | Medical Oncology | $25,102.25 |
| Bradley Somer | Germantown, TN | Hematology & Oncology | $14,101.08 |
| Laith Abushahin | Dallas, TX | Medical Oncology | $12,378.21 |
| Fadi Braiteh | Las Vegas, NV | Medical Oncology | $10,608.00 |
| Zev Wainberg | Santa Monica, CA | Hematology & Oncology | $9,262.25 |
| Christine Parseghian | Houston, TX | Medical Oncology | $6,755.03 |
| Maria Timis | Plano, TX | Family | $5,786.34 |
| John Marshall | Washington, DC | Hematology & Oncology | $5,278.74 |
| Guillermo Argiles-Martine | New York, NY | Medical Oncology | $4,500.00 |
Prescribed Vectibix?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.